Pineoblastoma Deep Research

Disease anchor

Preferred disease-level term: MONDO:0016722 pineoblastoma.
Oncology-specific histopathology grounding used in the disease entry: NCIT:C9344 Pineoblastoma and NCIT:C3264 Embryonal Neoplasm.
Disease-level modeling choice: one Pineoblastoma dismech page with flat subtype facets, not separate pages for every ontology subclass or molecular subgroup.

The mechanism graph unit is the disease entry, so the file is kb/disorders/Pineoblastoma.yaml, not separate files for PB-miRNA1, PB-miRNA2, PB-MYC/FOXR2, or PB-RB1.
disease_term is MONDO-first: MONDO:0016722.
NCIT is added where schema-supported and materially useful for oncology specificity, especially histopathology and morphology.
Molecular subgroup labels are modeled as flat subtype facets with classification: epigenetic consensus subgroup.
Subtype labels provide grounding and slicing context only; they do not imply separate disease pages or "Not Yet Curated" badges.

Older methylation-era nomenclature from PMID:31802236: PB-A, PB-B, PB-B-like, PB-FOXR2
Updated epigenetic consensus nomenclature from PMID:41291966: PB-miRNA1, PB-miRNA2, PB-MYC/FOXR2, PB-RB1
Mapping implication for curation: the older names should be treated as earlier cohort labels, while the current disease entry should foreground the 2025 consensus groups.

PMID:31768671 reports that alterations affecting DROSHA, DGCR8, or DICER1 occur in about two thirds of the core pineoblastoma subtypes.
PMID:41291966 refines this into the PB-miRNA1 and PB-miRNA2 consensus groups, with characteristic microRNA-processing gene alterations and frequent chromosome 7 gain / chromosome 14 loss.
PMID:39992227 connects germline DROSHA pathogenic variants to inherited pineoblastoma predisposition and places all analyzed predisposition tumors in the miRNA processing-altered 1 subgroup.

PMID:40240142 provides mechanistic model-organism evidence that loss of Drosha or Dicer1 in the developing pineal gland causes tumors with loss of mature microRNAs, derepression of targets, S-phase upregulation, and impaired pinealocyte maturation.
The paper supports a mechanistic chain of: microRNA-processing loss -> mature microRNA depletion -> proliferation-differentiation imbalance.
PLAGL2 emerges there as a downstream progrowth target, but in the disease entry it is kept subordinate to the more established disease-level mechanism nodes rather than promoted to its own top-level subtype program.

PMID:31768671 defines a distinct Pin-RB subgroup that includes trilateral retinoblastoma and sporadic pineal tumors with RB1 alterations.
PMID:41291966 incorporates this biology into the consensus PB-RB1 subgroup and notes especially poor outcomes in infants.
This justified a dedicated RB1 Pathway Inactivation mechanism node tagged to subtype PB-RB1, rather than splitting off a separate Pineoblastoma/RB1 disease file.

PMID:31802236 shows that PB-FOXR2 tumors universally overexpress FOXR2.
PMID:41291966 carries this forward as consensus PB-MYC/FOXR2.
This was modeled as a distinct subtype-tagged causal program (FOXR2 Oncogenic Activation) without creating a separate disease page.

PMID:41291966 reports OTX2 gain as the most frequent recurrent alteration across all pineoblastoma subtypes.
Because that event spans subtype boundaries, it belongs in the disease-level graph as a shared mechanism node, not as a subtype or separate disease file.

PMID:11767290 characterizes pineoblastoma as an embryonal tumor with photosensory differentiation, including Flexner-Wintersteiner rosettes and fleurettes.
PMID:6986979 identifies Homer Wright rosettes and cerebrospinal fluid spread as classic pineoblastoma findings.
Histopathology terms used in the disease entry: NCIT:C9344 Pineoblastoma HP:0031926 Homer Wright rosette HP:0031927 Flexner-Wintersteiner rosette NCIT:C35950 Fleurette Formation

PMID:32286280 notes that early symptoms include headache, ocular disturbance, ataxia, and hydrocephalus from increased intracranial pressure.
The disease entry uses ontology-grounded phenotype terms for the best-supported symptoms from that source: headache, ataxia, and hydrocephalus.

PMID:31802236 describes risk-adapted craniospinal irradiation and chemotherapy in SJMB03 and induction/consolidation/maintenance chemotherapy approaches in SJYC07.
PMID:40778560 adds a modern infant/young-child treatment pattern using maximal safe surgery followed by cyclophosphamide/etoposide/carboplatin and then craniospinal or focal irradiation depending on risk context.
The disease entry therefore focuses treatment curation on: maximal safe surgical resection, craniospinal irradiation, multi-agent chemotherapy.
Preclinical lysosome-disruption therapy from PMID:32286280 is kept in research context rather than represented as standard treatment, because it remains model-based and investigational.